CMG Pharmaceutical will manufacture pet treats and snacks and gradually include pet medications in its portfolio.
The Seoul-based company, part of the CHA Biomedical Group, confirmed to GlobalPETS that it is looking at a “variety of possibilities” with a focus on technology and investments in the pet industry.
AJU Daily reported earlier in the year that the medical company acquired ING Medix, a South Korean animal nutrition supplement maker. According to local media, the company would make use of its own distribution network to market and supply soft, chewy supplements.
In a statement to the press, CMG CEO Lee Ju-hyung said that it completed a hazard analysis procedure and is in the process of constructing smart factories.
He also stated that by 2030 the company aims to post annual sales of ₩50 billion ($38.5M/ €36M) in its pet business.
Pet ownership in the Asian country currently stands at 19.6%, according to a recent report by Statista
The latest articles
US: majority of pet owners still underestimate pet obesity
Obesity rates among cats and dogs in America have risen in the past 15 years, with the increase particularly pronounced in cats.
Pet Care
10 Oct 2024
French fermentation player acquires majority stake in Biorigin
Lesaffre, a global yeast manufacturer based in France, will become the controlling shareholder of the Brazilian company.
Global Pet Industry
10 Oct 2024
New proposals seek to expand tax benefits for vet care in the US
Two bills aim to expand vet care tax relief benefits and strengthen protections for dogs used for breeding.
Pet Care
9 Oct 2024
GET THE NEWSLETTER
Weekly newsletter to stay up-to-date
Discover what’s happening in the pet industry. Get the must-read stories and insights in your inbox.